Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of a Novel, First-in-Class Modulator of Eukaryotic Translation Initiation Factor 5A (eIF5A) in Patients (pts) with Relapsed or Refractory B-Cell Malignancies: Data from a Phase 1-2 Study

Alice S Bexon, MD, Michael Craig, MD, David S. Siegel, MD PhD, William Bensinger, Nicolas Novitzky, MD PhD, Andrew McDonald, MBChB, Martin Gutierrez, MD, Edward N. Libby, MD, Frits van Rhee, MD PhD, Jeremy Heidel, PhD, John Thompson, Charles Barranco, Catherine A Taylor, Kathleen A. Donovan, PhD, Laurie L. Moon-Tasson, BA, Leslie J. Browne, PhD, Michael R. Kurman, MD, John A. Lust, MD PhD, Richard Dondero

Blood (2014) 124 (21): 2121.

https://doi.org/10.1182/blood.V124.21.2121.2121

Published: 2014

Journal Articles

Interplay Between IL-1, IL-6 and IL-17 in IL-1 Receptor Antagonist (IL-1Ra) Treated Multiple Myeloma Patients

Kathleen A. Donovan, PhD, Laurie L. Moon-Tasson, BA, John A Lust, MD, PhD

Blood (2012) 120 (21): 1874.

https://doi.org/10.1182/blood.V120.21.1874.1874

Published: 2012

Journal Articles

Functional P2X7 Receptors in Myeloma Cell Lines and Myeloma Patient Bone Marrow Samples Can Be Blocked by Specific P2X7 Receptor Antagonists: Implications for Myeloma Therapy and Chemotherapy Induced Inflammation.

Kathleen A. Donovan, PhD, Laurie L. Moon-Tasson, BA, Alexander E. Hromockyj, PhD, Debra M Meyer, PhD, Andrew D Stone, Michael J Lust, John A Lust, MD, PhD

Blood (2011) 118 (21): 1845.

https://doi.org/10.1182/blood.V118.21.1845.1845

Published: 2011

Journal Articles

Long Term Follow-up of IL-1 Receptor Antagonist and Dexamethasone Phase II Clinical Trial in Patients with Smoldering/Indolent Myeloma Shows Improved Survival in Responsive Patients: Implications for Targeting Interleukin-1 Induced IL-6 Production and the Myeloma Proliferative Component

John A Lust, MD, PhD, Martha Q Lacy, MD, Steven R Zeldenrust, MD, PhD, Angela Dispenzieri, MD, Morie A Gertz, MD, Philip R. Greipp, MD, Thomas E. Witzig, MD, Shaji Kumar, MD, Laurie L. Moon-Tasson, BA, S. Vincent Rajkumar, MD, Kathleen A. Donovan, PhD

Blood (2011) 118 (21): 2945.

https://doi.org/10.1182/blood.V118.21.2945.2945

Published: 2011

Journal Articles

Preclinical Studies Using Polyethylenimine (PEI) Nanoparticles Complexed with Eukaryotic Translation Initiation Factor 5A (eIF5A) siRNA and eIF5A K50R Plasmid DNA Demonstrates Significant Anti-Myeloma Activity in Vitro and in Vivo

John A. Lust, MD, PhD, John E. Thompson, PhD, Catherine A. Taylor, PhD, Bin Ye, Zhongda Liu, Zhong Sun, Richard S. Dondero, PhD, Laurie L. Moon-Tasson, Michael P. Kline, PhD, Kathleen A. Donovan, PhD

Blood (2008) 112 (11): 249.

https://doi.org/10.1182/blood.V112.11.249.249

Published: 2008

Journal Articles

ITF2357, a Novel Histone Deacetylase Inhibitor, Demonstrates Significant Apoptotic Activity Against Human Multiple Myeloma Cells.

Michael Kline, PhD, Kathleen A. Donovan, PhD, John A. Lust, MD, PhD

Blood (2007) 110 (11): 4791.

https://doi.org/10.1182/blood.V110.11.4791.4791

Published: 2007

Journal Articles

Clinical and Biologic Studies in Smoldering/Indolent Multiple Myeloma (SMM/IMM) Suggest That Therapies That Specifically Inhibit IL-6 Production Are More Effective at Targeting the Proliferative Myeloma Component Than Apoptosis Inducing Agents.

John A. Lust, MD, PhD, Martha Q. Lacy, MD, Steven R. Zeldenrust, MD, PhD, Angela Dispenzieri, MD, Morie A. Gertz, MD, Philip R. Greipp, MD, Thomas E. Witzig, MD, Shaji Kumar, MD, Susan M. Geyer, PhD, Laurie L. Moon-Tasson, S. Vincent Rajkumar, MD, Kathleen A. Donovan, PhD

Blood (2006) 108 (11): 3500.

https://doi.org/10.1182/blood.V108.11.3500.3500

Published: 2006

Journal Articles

In Smoldering/Indolent (SMM/IMM) Myeloma Patients Treated with Interleukin-1 Receptor Antagonist (IL-1Ra), Responders Demonstrate a Significantly Increased Time to Progression (TTP) and a Decreased C-Reactive Protein (CRP) Compared with Nonresponders.

John A. Lust, MD, PhD, Martha Q. Lacy, MD, Steven R. Zeldenrust, MD, PhD, Angela Dispenzieri, MD, Morie A. Gertz, MD, Philip R. Greipp, MD, Thomas E. Witzig, MD, Susan M. Geyer, PhD, Laurie L. Moon-Tasson, S. Vincent Rajkumar, MD, Kathleen A. Donovan, PhD

Blood (2005) 106 (11): 2567.

https://doi.org/10.1182/blood.V106.11.2567.2567

Published: 2005

Journal Articles

Interleukin-1 Receptor Antagonist (IL-1Ra) Targets the Proliferative Component in Early Stage Myeloma.

John A. Lust, MD, PhD, Martha Q. Lacy, MD, Angela Dispenzieri, MD, Morie A. Gertz, MD, Steven R. Zeldenrust, MD, PhD, Philip R. Greipp, MD, Thomas E. Witzig, MD, Antje Hoering, PhD, Laurie L. Moon-Tasson, Michael M. Timm, MD, S. Vincent Rajkumar, MD, Kathleen A. Donovan, PhD

Blood (2004) 104 (11): 2412.

https://doi.org/10.1182/blood.V104.11.2412.2412

Published: 2004

NARROW

Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of a Novel, First-in-Class Modulator of Eukaryotic Translation Initiation Factor 5A (eIF5A) in Patients (pts) with Relapsed or Refractory B-Cell Malignancies: Data from a Phase 1-2 Study

Interplay Between IL-1, IL-6 and IL-17 in IL-1 Receptor Antagonist (IL-1Ra) Treated Multiple Myeloma Patients

Functional P2X7 Receptors in Myeloma Cell Lines and Myeloma Patient Bone Marrow Samples Can Be Blocked by Specific P2X7 Receptor Antagonists: Implications for Myeloma Therapy and Chemotherapy Induced Inflammation.

Long Term Follow-up of IL-1 Receptor Antagonist and Dexamethasone Phase II Clinical Trial in Patients with Smoldering/Indolent Myeloma Shows Improved Survival in Responsive Patients: Implications for Targeting Interleukin-1 Induced IL-6 Production and the Myeloma Proliferative Component

Preclinical Studies Using Polyethylenimine (PEI) Nanoparticles Complexed with Eukaryotic Translation Initiation Factor 5A (eIF5A) siRNA and eIF5A K50R Plasmid DNA Demonstrates Significant Anti-Myeloma Activity in Vitro and in Vivo

ITF2357, a Novel Histone Deacetylase Inhibitor, Demonstrates Significant Apoptotic Activity Against Human Multiple Myeloma Cells.

Clinical and Biologic Studies in Smoldering/Indolent Multiple Myeloma (SMM/IMM) Suggest That Therapies That Specifically Inhibit IL-6 Production Are More Effective at Targeting the Proliferative Myeloma Component Than Apoptosis Inducing Agents.

In Smoldering/Indolent (SMM/IMM) Myeloma Patients Treated with Interleukin-1 Receptor Antagonist (IL-1Ra), Responders Demonstrate a Significantly Increased Time to Progression (TTP) and a Decreased C-Reactive Protein (CRP) Compared with Nonresponders.

Interleukin-1 Receptor Antagonist (IL-1Ra) Targets the Proliferative Component in Early Stage Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only